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Down-regulation of hepatic lipase expression in experimental
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Down-regulation of hepatic lipase expression in experimental nephrotic
syndrome. Hepatic lipase (HL) plays an important role in catabolism of
chylomicron remnants, conversion of intermediate density lipoprotein
(IDL) to low-density lipoprotein (LDL) and reverse transport of choles-
terol to the liver. Several features of the nephrofic dyslipidemia point to
the possible presence of HL deficiency. In an attempt to address this
possibility, gene expression of HL was studied in rats with puromycin-
induced nephrotic syndrome (NS). The results were compared with those
obtained in a group of placebo-treated control animals. The NS group
showed marked proteinuria, hypoalbuminemia, hypercholesterolemia, hy-
pertriglyceridemia, normal creatinine clearance and normal hepatic tissue
cholesterol concentration. HL activity of the liver tissue was reduced by
approximately 60% in the NS group as compared to that found in the
normal control group. The reduction of HL activity in the NS group was
accompanied by a reduction of HL mRNA of virtually similar magnitude.
HL activity of the liver tissue was inversely related to urinary protein
excretion, serum cholesterol and serum triglyceride concentrations. In
contrast, HL activity was directly related to serum albumin concentration
and HL mRNA. No significant difference was observed in HL activity
between the control group and the pre-nephrotic animals studied at days
1 and 5 following puromycin administration. This observation excludes an
acute effect of puromycin as a possible cause of HL deficiency in the NS
animals. Thus, NS in this model results in a marked down-regulation of
1-IL expression which may, in part, contribute to the nephrotie dyslipide-
mia.
Hepatic lipase (HL) is a member of the large lipase gene family
that includes lipoprotein lipase (LPL) and pancreatic lipase (PL).
Both HL and LPL catalyze the hydrolysis of triglycerides con-
tained in plasma lipoproteins leading to release of the free fatty
acids, monoacyiglycerols and diacylglycerols. Despite their exten-
sive amino acid sequence homology [11, HL and LPL exhibit
several important functional differences: (a) HL is exclusively
produced by hepatocytes and after release becomes anchored to
the surface of hepatocytes and hepatic endothelial cells via
heparan sulfate receptors [2, 31. In contrast, LPL is primarily
produced by and localized to the adipose tissue, skeletal muscle
and myocardium. Thus, the two isoenzymes have distinct tissue
distributions. (b) In contrast to LPL, which requires Apo C-Il as
a cofactor for its optimal catalytic activity, HL activity does not
depend on a cofactor. (c) Due to its Apo C-Il independent
activity, HL can hydrolyze triglycerides in intermediate density
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lipoproteins (IDL) and chylomicron remnants that lack Apo C-Il
and, as such, cannot be hydrolyzed by LPL [4, 51. In addition, HL
serves as a phospholipase and as such helps to convert HDL-2 to
HDL-3 [6]. Thus, HL and LPL have distinct substrate specificities.
(d) In contrast to LPL, HL activity is not inhibited by high NaCl
concentrations (1 M NaC1). As can be seen from the foregoing
summary, LPL and HL play a complimentary and sequential role
in catabolism of triglyceride-laden lipoproteins, that is, chylomi-
crons and VLDL and their remnants. Thus, LPL and HL defi-
ciency can potentially lead to hypertriglyceridemia, elevation of
plasma VLDL, IDL and impaired clearance of chylomicrons and
their remnants. In a recent study, we have found marked down-
regulations of LPL expression in the heart, skeletal muscle and
adipose tissue in rats with experimental nephrosis (NS) [7]. In
view of the known association of NS with impaired post-heparin
lipolytic activity, abnormal composition of lipoproteins and eleva-
tion of plasma concentrations of triglycerides, VLDL and IDL
[8—i7], we hypothesized that, like LPL, HL expression may be
defective in NS. The present study was designed to test this
hypothesis.
Methods
Animal model
Male Sprague-Dawley rats (Harlan Sprague Dawley Inc., Indi-
anapolis, IN, USA) weighing 180 to 200 g were used. They were
housed in a temperature-controlled, light-regulated space with
12-hour night ( 5 lox) and 12-hour day (500 lox) cycles. The
animals were fed regular rat chow (Purina Mills Inc., Brentwood,
MO, USA) and water ad libitum. They were randomly assigned to
either the NS or normal control groups. Mimals randomized to
the NS group were given an intraperitoneal injection of puromy-
cm aminonucleoside (Sigma Chemical Inc., St. Louis, MO, USA),
130 mg/kg, on day 0 followed by a second injection, 60 mg/kg, on
day 14. The control animals were given placebo injections.
Subgroups of rats were studied on days 1, 5 and 30. On each
occasion, animals were placed in metabolic cages, and 24-hour
urine collections were obtained for measurements of protein and
creatinine prior to sacrifice. The animals were then anesthetized
(sodium pentobarbital, 50 mg/kg i.p.), the abdomen opened, and
the liver harvested immediately. The animals were subsequently
exsanguinated by cardiac puncture, and blood was secured for
measurements of creatinine, albumin, cholesterol and triglycer-
ides.
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Polymerase chain reaction
Polymerase chain reaction (PCR) was used to prepare a partial
eDNA probe for rat hepatic lipase (HL). To this end, two oh-
gonucleotide primers were used to amplify an 819 bp rat HL eDNA
fragment. The primers employed included rHL1 (nucleotide 313 to
324: 5' TGGATDTGGAAGATAGTGGGT 3') and rHL2 (nucleo-
tide 1111-1132:5' AGTAGGCTCTATTGGCYFCTC 3'). The com-
positions of these primers were derived from the published
sequence for rat HL [181. First strand cDNA was synthesized from
1 .rg rat liver poly(A4) RNA (used as template) employing a
cDNA cyclic kit (Invitrogene, San Diego, CA, USA). The eDNA
produced was then amplified by PCR in 50 pl of a solution
containing 10 m'vi Tris-HC1, 50 ms KCI, 1.5 m'vi MgC1, 200 /.LM
dNTP mixture (consisting of dATP, dCTP, dGTP and dTTP), 1 U
Taq polymerase and 1 sM of each primer. PCR amplification was
carried out for 30 cycles, each consisting of the following steps:
94°C, one minute; 55°C, one minute; and 72°C, one minute. The
PCR products were separated on 1% agarose gel, and the band
corresponding to the 800 base pairs was cut, isolated with a
Gene-Clean 228 II Kit (Qiagen Inc., Chatsworth, CA, USA), then
ligated to a PCR 228 II vector using a TA cloning kit (Invitro-
gene). Positive insert was sequenced by Sequenase Version 2.0 Kit
(United States Biochemical Co., Cleveland, OH, USA) on double
stranded DNA. To prepare the probe, approximately 0.8 Kb HL
cDNA insert was excised by EcoRI from the above clone.
RNA preparation and Northern blot analysis. At the conclusion
of each study period, the rats were killed between the hours of 9
and 11 a.m. The tissues were removed immediately, frozen in
liquid nitrogen and stored at —70°C until processed. Total RNA
was prepared from 1 g of liver with RNAzoI using the manufac-
turer's recommended procedure (Tel-Test Inc., Friendswood, TX,
USA) as previously described [191. RNA concentration was
determined from the absorbance at 260 nm using a spectropho-
tometer (Gene-Quat, Bio-Rad, Hercules, CA, USA). Thirty mi-
crogram aliquots of total RNA were denatured in 2.2 M formal-
dehyde at 65°C for 15 minutes and run on 1.0% agrose/2.2 M
formaldehyde gel at 46 V for four hours. The separated RNA was
transferred to the nylon membrane (Zeta probe, Bio-Rad) by
capillary blotting in 6>< SSC buffer overnight and immobilized by
UV irradiation (Ultraviolet Crosslinker; Fisher Scientific, Pitts-
burgh, PA, USA). The membrane was incubated at 65°C in a
solution containing 5 x SSPE, 5 x Denhard's solution, 1% SDS
and 100 jsg/ml salmon sperm DNA for two hours. The eDNA
probe for rat glyceraldehyde phosphate dehydrogenase
(GAPDH) (1.3 Kb PstI fragment) was obtained from American
Type Culture Collection (Rockville, MD, USA). The eDNA
probe for HL was prepared as described above. The probes were
labeled with [32P] dCTP (3000 Ci/mmol; New England Nuclear
Inc., Boston, MA, USA) by the random primer method (Promega
Inc., Madison, WI, USA). Hybridization was carried out at 65°C in
a prehybridization solution with 32P labeled cDNA. The blots
were washed twice in 2 X SSPE/0.5% SDS solution at room
temperature, twice in 1 X SSPE/0.5% SDS solution at 37°C, and
twice in 0.1 x SSPE/0.5% SDS solution at 65°C, for 15 minutes
each. The washed blots were exposed to X-ray film (New England
Nuclear Inc.) at —80°C for two days for GAPDH and five days for
HL. The autoradiographs were scanned with a laser densitometer
(Molecular Dynamics, Sunnyvale, CA, USA) to determine rela-
Table 1. Body weight, serum concentrations of albumin, cholesterol,
triglycerides and creatinine, 24-hour urinary protein excretion,
creatinine clearance and the liver size and hepatic tissue cholesterol
concentration in the nephrotic animals studied at day 30 and their
normal control counterparts
Normal
(N = 6)
Nephrotic(N = 6)
P
values
Body weight g 294.2 15.2 271.2 15.4 NS
Urine protein mg/24 hrs 7.5 0.8 261 21.1 <0.001
Serum cholesterol mgldl 69.8 3.5 298.2 20.3 <0.001
Serum VLDL mg/dl 7.8 1.0 48.8 6.7 <0.001
Serum triglyceride mg/dl 49.3 7.9 228.2 29.5 <(1.001
Serum albumin mg/dl 3.6 0.1 2.2 0.1 <0.001
Serum creatinine mg/dl 0.6 0.1 0.6 0.1 NS
Ccr mI/mm 1.1 0.2 1.2 0.1 NS
Liver weight g 10.3 0.4 13.4 0.4 <0.01
Liver cholesterol concentration 21.5 2.6 20.2 2.3 NS
mg/g wet liver
tive mRNA levels. The values obtained for constitutively ex-
pressed GAPDH gene were used as an internal control.
Tissue hepatic lipase activity assay. Hepatic lipase activity was
determined as described previously [20]. In brief, liver (100 mg)
was homogenized in 4 ml ice-cold buffer containing 0.15 M NaCI,
5 mM barbital buffer (pH 7.4) and 5 U/mI heparin [21]. The
homogenate was centrifuged at 13,000 X g at 4°C for 10 minutes,
and the supernatant obtained for measurement of hipase activity.
The supernatant was then incubated with an emulsified ['4C]
trioleoylglycerol substrate (Amersham Life Science Inc., Arling-
ton Heights, IL, USA) in the presence of 2 M NaCI to inhibit
hipoprotein lipase. HL activity was expressed as mU/mg protein.
One mU was defined as 1 nmol of free fatty acid released per
minute.
Data presentation and analysis
Student's t-test and regression analysis were used in statistical
analysis of data which are presented as mean SEM. P values
equal to or less than 0.05 were considered significant.
Results
General data
The NS animals exhibited heavy proteinuria, hypoalbuminemia
and marked elevations of plasma cholesterol and triglyceride
concentrations. However, plasma creatinine concentration and
creatinine clearance in the NS group were comparable to those
found in the normal control group. Accordingly, the NS animals
employed here did not have renal insufficiency. No significant
difference was found in hepatic tissue cholesterol concentration in
the two groups (Table 1).
HL activity and mRNA
The NS animals studied at day 30 exhibited a marked reduction
(60%) in HL activity when compared with the corresponding
value observed in the normal control group. The reduction in HL
activity in the NS animals was accompanied by a parallel fall in HL
mRNA of nearly identical magnitude (P < 0.01 for both HL
activity and mRNA relative to values found in the controls).
No significant difference was observed in HL activity between
the normal control group and the pre-nephrotic animals studied
at days 1 and 5 following puromycin administration. These
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Fig. 1. A representative autoradiograph of the Northern blot of hepatic lipase
(HL) and the corresponding GAPDH in the normal control group (NL)
(lanes 1, 2 and 3) and nephrotic rats (NS) at day 30 (lanes 4, 5 and 6). Total
RNA (30 tg/lane) was isolated from liver as described in the Methods
sect ion, and separated by electrophoresis on 1.0% agarose/2.2 M formal-
dehyde gel. RNA was transferred to a nylon filter and hybridized with the
32P-labeled 0.8 Kb eDNA to rat HL mRNA and 1.3 Kb eDNA to rat
GAPDH mRNA that was used as control.
observations tend to argue against the acute effect of puromycin,
per se, as a possible cause of the observed HL deficiency (Figs. I
to 3).
Correlations
A significant positive correlation was found between urinary
protein excretion and plasma concentrations of triglycerides (r =
0.93, P < 0.01), and cholesterol (r = 0.95, P < 0.01). Tn contrast,
urinary protein excretion was inversely related to liver tissue HL
activity (r = —0.89, P < 0.01), whereas plasma albumin concen-
tration was directly related to HL activity (r = 0.84, P < 0.01). A
strong correlation was found between HL activity and mRNA in
the study population (r = 0.82, P < 0.01).
Discussion
Nephrotic syndrome is associated with hypercholesterolemia,
hypertriglyceridemia and elevated plasma concentrations of LDL
and VLDL and normal or reduced concentration of HDL leading
to a high LDL-to-HDL ratio [221. In addition, plasma concentra-
tions of VLDL remnants (IDL) and chylomicron remnants con-
taining abnormally high phospholipid and esterified and unester-
ified cholesterol are markedly increased in NS [23]. In this regard,
hepatic clearance of chylomicron remnants and IDL are reduced
in rats with NS induced by either puromycin aminonucleoside or
Heyman nephritis [17]. Given the known role of HL in hepatic
catabolism of IDL and chylomicron remnants and its additional
property as a phospholipase, HL deficiency can potentially con-
tribute to the above abnormalities.
The NS animals employed in the present study exhibited a
significant reduction in HL activity as compared to the value
obtained in the normal control group. The reduction in HL
activity in the NS group was accompanied by a parallel reduction
in the liver HL mRNA. These observations suggest that NS in this
model leads to acquired HL deficiency. The data further indicate
that the down regulation of HL in this model occurs at the mRNA
level. The latter is supported by the strong direct correlation
between the HL activity and mRNA values in the study popula-
tion.
In a recent study, we have found a marked LPL deficiency in the
heart, skeletal muscle and adipose tissue of rats with experimental
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Fig. 2. A. Comparison of I-IL activity in the normal control group (NL) and
nephrotic rats (NS). HL activity was measured from homogenate of the
liver as described in the Methods section. The results are given in mU/mg
protein. One mU is defined as 1 nmol of free fatty acid released from the
substrate per minute. Data are given as mean SEM. N 6. B. Group data
comparing the HL/GAPDH mRNA ratios in the study populations (N =
6 for each group). Data are given as meanSEM. *D < 0.01.
NS [7]. Together LPL and HL deficiencies can contribute to the
defective peripheral and hepatic catabolism of chylomicrons,
VLDL and their remnants as shown by Kaysen et al [17].
Likewise, deficiencies of these heparin-releasable lipases can
account for the reduction of post-heparin lipolytic activity in NS
[15, 17].
Chronic renal insufficiency is associated with marked down-
regulations of HL, LPL and VLDL receptor expressions [24—26].
The NS animals employed here had normal serum creatinine and
creatinine clearance values. Therefore, down-regulation of HL
expression in the NS animals was not due to renal insufficiency.
In an attempt to exclude the acute effect of puromycin as a
possible cause of the observed down-regulation of ML expression,
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Fig. 3. Comparison of HL activity in the normal control group (NL) and the
pre-nephrotic rats studied on days 1 (DI) and 5 (D5) after puromycin
injection. Data are given as mean SEM. N = 6 in each subgroup.
subgroups of animals were studied one and five days after
puromycin injection at which point proteinuria was absent. The
results showed no significant change in either HL activity or
mRNA in the puromycin-treated pre-nephrotic animals. This
observation suggests that HL deficiency in the NS animals is not
due to acute exposure to puromycin per Se.
The mechanism(s) responsible for down-regulation of HL
expression in this model of NS is unclear. Further studies are
required to address this issue. HL, LPL, and VLDL receptors
work in concert to maintain normal rates of catabolism of tri-
glyceride-rich lipoproteins. Down-regulation of HL expression
shown here and those of LPL and VLDL receptors found before
[7, 27] can account for the defective catabolism of triglyceride-rich
lipoproteins and the resulting abnormalities of their plasma
profile in NS.
HL plays a major role in catabolism of VLDL and chylomicron
remnants as well as conversion of IDL to LDL and HDL-2 to
HDL-3. Therefore, in addition to its role in triglyceride metabo-
lism, HL plays an important part in cholesterol metabolism by
acting at several steps involved in reverse cholesterol transport.
Accordingly, HL facilitates cholesterol transport into the hepato-
cytes [3—6, 28]. Based on these observations, acquired HL defi-
ciency, shown here, together with LDL receptor deficiency, shown
earlier [19], contribute to the lack of increase in hepatic choles-
terol content in this model despite severe hypercholesterolemia.
The latter phenomenon has been causally linked to dysregulation
in NS of HMG-CoA reductase and cholesterol 7a-hydroxylase
expression which are primarily regulated by microsomal choles-
terol concentration [29, 301. Thus, HL deficiency not only plays a
part in the genesis of hypertriglyceridemia, but also that of
hypercholesterolemia in NS. This supposition is supported by the
strong inverse correlation of HL activity with plasma concentra-
tions of both triglycerides and cholesterol.
In a recent study Shafrir reported mild elevation of HL activity
in rats rendered proteinuric by a single i.v. injection of puromycin
(30 mg/kg) [31]. The result of the latter report contrasts that of the
present study which showed significant reduction in HL activity in
the nephrotic animals. The reason for the difference in HL activity
in the two studies is unclear. However, we measured HL activity
at multiple points in fresh hepatic tissue preparations in the
presence of 2 M NaCI to inactivate lipoprotein lipase. In contrast,
in Shafrir's study, HL activity was determined at a single point
using acetone powder extract of the liver tissue in the absence of
serum to minimize lipoprotein lipase activation. Moreover, the
NS model employed here was different from that used in the latter
study. It should be noted that the NS animals employed here
exhibited parallel reductions of HL activity and mRNA during the
course of NS, providing strong evidence for HL deficiency at the
molecular level. No mRNA measurements were carried out in the
study reported by Shafrir. In addition, impaired lipoprotein
remnant clearance known to occur in NS tends to provide a
physiologic basis for the presence of HL deficiency shown here.
In summary, the present study revealed a marked down-
regulation of hepatic lipase expression in rats with puromycin-
induced nephrotic syndrome. This abnormality can, in part,
account for the hypertriglyceridemia, hypercholesterolemia and
increased plasma concentration and abnormal composition of
IDL and chylomicron remnants in NS.
Reprint requests to ND. Vaziri, M.D., Division of NephroIo, Department
of Medicine, UCI Medical Center, 101 The City Drive, Orange, Califi.)rnia
92868, USA.
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